Antitumor effect of whole body hyperthermia with α-galactosylceramide in a subcutaneous tumor model of colon cancer

References

• Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, Felix R, Riess H. The cellular and moolecular basis of hyperthermia. Crit Rev Oncol Hematol 2002; 43: 33–56
   PubMed Web of Science ®Google Scholar
• Wust P, Hildebrandt B, Sreenivasa G, Rau B, Ge llermann J, Riess H, Felix R, Schlag PM. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002; 3: 487–497
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Oyamada H, Ichikawa H, Naito Y, Ueda S, Tainaka K, Itani K, Seto O, Sugino S, Kondo M. Antitumor effect and indication of chemoembolization using degradable starch microspheres and regional hyperthermia in patients with hepatocellular carcinoma. J Jpn Soc Cancer Ther 1989; 24: 786–792
   PubMedGoogle Scholar
• Schulze T, Wust P, Gellermann J, Hildebrandt B, Riess H, Felix R, Rau B. Influence of neoadjuvant radiochemotherapy combined with hyperthermia on the quality of life in rectum cancer patients. Int J Hyperthermia 2006; 22: 301–318
   PubMed Web of Science ®Google Scholar
• Calderwood SK, Theriault JR, Gong J. How is the immune response affected by hyperthermia and heat shock proteins? Int J Hyperthermia 2005; 21: 713–716
   PubMed Web of Science ®Google Scholar
• Manjili MH, Wang XY, Park J, Macdonald IJ, Li Y, Van Schie R, Subjeck JR. Cancer immunotherapy: Stress proteins and hyperthermia. Int J Hyperthermia 2002; 18: 506–520
   PubMed Web of Science ®Google Scholar
• Tanaka K, Ito A, Kobayashi T, Kawamura T, Shimada S, Matsumoto K, Saida T, Honda H. Intratumoral injection of immature dendritic cells enhances antitumor effect of hyperthermia using magnetic nanoparticles. Int J Cancer 2005; 116: 624–633
   PubMed Web of Science ®Google Scholar
• Baronzio G, Gramaglia A, Fiorentini G. Hyperthermia and immunity. In Vivo 2006; 20: 689–695
   PubMed Web of Science ®Google Scholar
• Morita M, Motoki K, Akimoto K, Natori T, Sakai T, Sawa E, Yamaji K, Koezuka Y, Kobayashi E, Fukushima H. Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. J Med Chem 1995; 38: 2176–2187
   PubMed Web of Science ®Google Scholar
• Nakagawa R, Motoki K, Ueno H, Iijima R, Nakamura H, Kobayashi E, Shimosaka A, Koezuka Y. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000. Cancer Res 1998; 58: 1202–1207
   PubMed Web of Science ®Google Scholar
• Fuji N, Ueda Y, Fujiwara H, Toh T, Yoshimura T, Yamagishi H. Antitumor effect of alpha-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver. Clin Cancer Res 2000; 6: 3380–3387
   PubMed Web of Science ®Google Scholar
• Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 1995; 7: 529–534
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Motoki K, Ueno H, Maeda K, Kobayashi E, Inoue H, Fukushima H, Koezuka Y. Enhancing effects of (2S,3S,4R)-1-O-(alpha-D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4-octadecanetriol (KRN7000) on antigen-presenting function of antigen-presenting cells and antimetastatic activity of KRN7000-pretreated antigen-presenting cells. Oncol Res 1996; 8: 399–407
   PubMed Web of Science ®Google Scholar
• Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Sato H, Kondo E, Harada M, Koseki H, Nakayama T, Tanaka Y, Taniguchi M. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci USA 1998; 95: 5690–5693
   PubMed Web of Science ®Google Scholar
• Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, Koseki H, Taniguchi M. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997; 278: 1626–1629
   PubMed Web of Science ®Google Scholar
• Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: Facts, functions and fallacies. Immunol Today 2000; 21: 573–583
   PubMedGoogle Scholar
• Smyth MJ, Godfrey DI. NKT cells and tumor immunity a double-edged sword. Nat Immunol 2000; 1: 459–460
   PubMed Web of Science ®Google Scholar
• Lejeune FJ, Eggermont AM. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs. J Clin Oncol 2006; 24: 4196–4201
   PubMedGoogle Scholar
• Siddiqui F, Ehrhart EJ, Charles B, Chubb L, Li CY, Zhang X, Larue SM, Avery PR, Dewhirst MW, Ullrich RL. Anti-angiogenic effects of interleukin-12 delivered by a novel hyperthermia induced gene construct. Int J Hyperthermia 2006; 22: 587–606
   PubMed Web of Science ®Google Scholar
• Corbett TH, Griswold DP, Jr, Roberts BJ, Peckham JC, Schabel FM, Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assay, with a note on carcinogen structure. Cancer Res 1975; 35: 2434–2439
   PubMed Web of Science ®Google Scholar
• Koga T, Harada H, Shi TS, Okada S, Suico MA, Shuto T, Kai H. Hyperthermia suppresses the cytotoxicity of NK cells via down regulation of perforin/granzyme B expression. Biochem Biophys Res Commun 2005; 337: 1319–1323
   PubMed Web of Science ®Google Scholar
• Gately MK, Glaser M, Dick SJ, Mettetal RW, Jr, Kornblith PL. In vitro studies on the cell-mediated immune response to human brain tumors. I. Requirement for third-party stimulator lymphocytes in the induction of cell-mediated cytotoxic responses to allogeneic cultured gliomas. J Natl Cancer Inst 1982; 69: 1245–1254
   PubMedGoogle Scholar
• Robins HI, Dennis WH, Neville AJ, Shecterle LM, Martin PA, Grossman J, Davis TE, Neville SR, Gillis WK, Rusy BF. A nontoxic system for 41.8°C whole-bodyhyperthermia: Results of a Phase I study using a radiant heat device. Cancer Res 1985; 45: 3937–3944
   PubMed Web of Science ®Google Scholar
• Sawaji Y, Sato T, Takeuchi A, Hirata M, Ito A. Anti-angiogenic action of hyperthermia by suppressing gene expression and production of tumour-derived vascular endothelial growth factor in vivo and in vitro. Br J Cancer 2002; 86: 1597–1603
   PubMed Web of Science ®Google Scholar
• Uehara M, Inokuchi T. Hyperthermic photodynamic therapy combined with topical administration of OK-432 in the mouse carcinoma. Oral Oncol 2003; 39: 184–189
   PubMedGoogle Scholar
• Yamada T, Hayashi Y, Kaneko R, Tohnai I, Ueda M, Ito M. Effect of the combination of a local OK-432 injection and hyperthermia on SCC VII tumors in mice. J Radiat Res 1998; 39: 101–109
   PubMedGoogle Scholar
• Taradi SK, Taradi M, Urano M. Effect of thermoimmunotherapy with OK-432 on the development of spontaneous lung metastases in mice. Int J Hyperthermia 1992; 8: 221–226
   PubMed Web of Science ®Google Scholar
• Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 1995; 7: 529–534
   PubMed Web of Science ®Google Scholar
• Nakagawa R, Nagafune I, Tazunoki Y, Ehara H, Tomura H, Iijima R, Motoki K, Kamishohara M, Seki S. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by α-galactcylceramide in mice. J Immunology 2001; 166: 6578–6584
   PubMed Web of Science ®Google Scholar
• Lindahl P, Leary P, Gresser I. Enhancement by interferon of the specific cytotoxity of sensitized lymphocytes. Proc Natl Acad Sci USA 1972; 69: 721–725
   PubMed Web of Science ®Google Scholar
• Kataoka T, Matsuura N, Oh-hashi F, Suhara Y. Treatment regimen and host T-cell dependent therapeutic effects of interferon in mouse solid tumors. Cancer Res 1985; 45: 3548–3553
   PubMed Web of Science ®Google Scholar
• Noessner E, Gastpar R, Milani V, Brandl A, Hutzler PJ, Kuppner MC, Roos M, Kremmer E, Asea A, Calderuood SK, Issels RD. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunology 2002; 169: 5424–5432
   PubMed Web of Science ®Google Scholar
• Atanackovic D, Nierhaus A, Neumeier M, Hossfeld DK, Hegewisch-Becker S. 41.8°C whole body hyperthermia as an adjunct to chemotherapy induces prolonged T cell activation in patients with various malignant diseases. Cancer Immunol Immunother 2002; 51: 603–613
   PubMed Web of Science ®Google Scholar
• Takahashi T, Mitsuhashi N, Sakurai H, Niibe H. Modifications of tumor-associated antigen expression on human lung cancer cells by hyperthermia and cytokine. Anticancer Res 1995; 15: 2601–2606
   PubMed Web of Science ®Google Scholar
• Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: Chaperoning of the innate and adaptive immune responses. Ann Rev Immunol 2002; 20: 395–425
   PubMed Web of Science ®Google Scholar